Gandeeva Therapeutics
Gandeeva Therapeutics uses the most advanced cryo-EM and computational tools to develop better therapies for patients.
Gandeeva Therapeutics uses the most advanced cryo-EM and computational tools to develop better therapies for patients.
Gandeeva Therapeutics is a precision biotechnology company with a vision to revolutionize therapy development using cutting-edge technology. Leveraging cryo-EM and machine learning, the company aims to develop novel therapies by targeting and modulating key protein-protein interactions. Their structure-guided drug discovery platform, encompassing target prediction and validation (SPOTLIGHT™), hit identification (HYPERFOCUS™), and lead optimization (CRYO-CADD™), showcases their commitment to innovation. Headquartered in Canada and founded in 2021, Gandeeva has already secured a significant $40.00M Series A investment from prominent investors including Air Street Capital, Lux Capital, Obvious Ventures, Amgen Ventures, Amplitude Ventures, and Leaps by Bayer, demonstrating strong support for their groundbreaking approach. With a robust preclinical pipeline focusing on challenging cancers, Gandeeva Therapeutics is poised to make a significant impact in Biotechnology and Health Care sectors.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series A | $40.00M | 6 |
|
31 Jan 2022 |
No recent news or press coverage available for Gandeeva Therapeutics.
We care about your data, and we'd love to use cookies make your experience better.
